A Facile Synthesis of Some Novel Thiazoles Arylazothiazoles and Pyrazole Linked To Thiazolyl Coumarin As Antibacterial Agents
A Facile Synthesis of Some Novel Thiazoles Arylazothiazoles and Pyrazole Linked To Thiazolyl Coumarin As Antibacterial Agents
Anhar Abdel-Aziem, Basma Saad Baaiu, Awad Wanis Elbazzar & Fakhri
Elabbar
To cite this article: Anhar Abdel-Aziem, Basma Saad Baaiu, Awad Wanis Elbazzar & Fakhri
Elabbar (2020) A facile synthesis of some novel thiazoles, arylazothiazoles, and pyrazole linked
to thiazolyl coumarin as antibacterial agents, Synthetic Communications, 50:16, 2522-2530, DOI:
10.1080/00397911.2020.1782431
Article views: 94
GRAPHICAL ABSTRACT
S N
NH
H
Br N N N
N N
R HN
S O
OH
S
Br CHO Br N NH2
N H
OH R= O O
Y
S N
N
R N X
CONTACT Anhar Abdel-Aziem [email protected] Chemistry Department, Faculty of Science (Girls), Al-Azhar
University, Nasr City, Cairo, Egypt.
Supplemental data for this article can be accessed on the publisher’s website.
ß 2020 Taylor & Francis Group, LLC
SYNTHETIC COMMUNICATIONSV
R
2523
Introduction
Thiazoles are considered an important class of heterocyclic compounds both biologically
and chemically. Previous studies have shown that thiazole based-compounds had effective
pharmacological importance with antimicrobial,[1–8] anti-inflammatory,[9–11] anticonvul-
sant,[12,13] anti-diabetic,[14–16] anti-HIV[17,18] antitumor,[19–26] and antioxidant[27,28] activ-
ities. Moreover, a variety of natural products contain thiazole scaffold such as thiamin
(vitamin B1) and thiamin pyrophosphate (TPP). Mycothiazole is isolated from sponge
spongia mycofijiensis and shows a selective activity against lung cancer.[29] The antibiotic
cystothiazole A was isolated from the myxobacterium culture by Sakagami et al. in 1998.
In particular, thiazoles are found in many powerful biologically active synthetic drugs
(Figure 1).
On the other hand, coumarins occur in the seeds, roots, and leaves of a large number
of plants,[30] fungi, bacteria, and marine sources.[31] Coumarins exhibit diverse bio-
logical activities as antimicrobial[32] anticancer and anti-inflammatory,[33–35] antioxi-
dant,[36] antiviral,[37] and anti-tubercular. [38] Warfarin is a coumarin derivative which
possesses anticoagulant properties, used to treat or prevent blood clots in veins.[39]
Furthermore, thiazolyl coumarin moiety has antimicrobial, anticancer, and antifibrotic
activities.[40–44] Also, pyrazolyl thiazolyl coumarin is antimicrobial agents.[45] Based on
the above facts, herein, we decided to prepare new thiazoles, molecular hybrids based
on pyrazole-thiazole-coumarin (PTC), and study their antibacterial activities.
H S
N H O N
N S NH2 N O
S O H
O O O
Sulfathiazole Penicillin
(antimicrobial drug) (Antibiotic)
CN
S
H N
O OH H N N
F
S
O
N N
N S
F H N O O
Ravuconazole Meloxicam
(Antifungal) (Anti-inflammatory)
OCH3OCH3
N S
OCH3 S N
H3CO O
cystothiazole A
(Antibiotic)
H
Br N N
N O
S
OH
Br CHO 3
OH O
1 Cl
O
O Br
H
N NH2 CH2Br H
H2N H Br N N
Br N NH2 O O N
S N R
S S
OH
OH
2 4
R O Br
X
O R=
Cl N O O
N
O N HN
H
Cl
H H
Br N N Br N N
N O
N R
S S
OH OH
5a,b N N
6a,b N NH
a, X= H, b; X=Cl a, R = CH3; b, R = Ph
S
Br N N
O NH
Br Br O O O
N N
12
H
O O O
7 N N
H H
N NH2 O
H2N Cl
S
S Y
O O S N
Br N NH2 Br N
N H N
X
O O O O
8 X= CH3, CF3, OC2H5
9a-c
10a-c
(CH3CO)2C=NNHAr 9a, Y= CH3; b, Y= CF3; c, Y= OH
S N
Br N N=N Ar
N
O O
11a-c
10,11: a, Ar = C6H5; b, Ar = 4-CH3C6H4; c, Ar = 4-FC6H4
Antibacterial activity
All the tested microorganisms were chosen based on their pathogenicity. The organisms
were tested against the activity of solutions with one concentration; 100 mg/ml and then
10 ml of preparation was dropped on disk of 6 mm in diameter and the concentrations
became 1 mg/disk. In the case of insoluble compounds, the compounds were suspended
in DMF and vortexed then processed. Chloramphencol was used as standard reference
in the case of Gram-negative bacteria, Cephalothin was used as standard reference in
the case of Gram-positive bacteria. The results were depicted in Table 1. The investiga-
tion of antibacterial screening data revealed that, compounds 5a, 5b, 9a, 9c, 11b, and
12 were strong active towards Gram-positive bacteria Enterococcus faecalis, while com-
pounds 3, 4, 6a, 6b, and 9b were intermediate active. All the tested compounds showed
intermediate activity towards Staphylococcus aureus except compound 5a which was
strongly active and compounds 6a, 9a, and 12 which was low active. For Gram-negative
bacteria, all the tested compounds showed intermediate to low activity except com-
pounds 9b, 11b, and 12 were strong active towards Pseudomonas aeruginosa.
Experimental section
All reagents and solvents were of commercial grade. Melting points were determined on
the digital melting point apparatus and were uncorrected. 1H and 13C NMR spectra
were measured with a Bruker Avance spectrometer (Bruker, Germany) at 400 and
101 MHz, respectively, using TMS as the internal standard. Hydrogen coupling patterns
were described as singlet (s), doublet (d), triplet (t), quartet (q) and multiplet (m).
Chemical shifts were defined as parts per million (ppm) relative to the solvent peak.
Elemental analyses were performed on CHNS-O analyzer (Perkin-Elmer, USA).
Hydrazonoyl halides[48–50] were prepared as previously reported.
SYNTHETIC COMMUNICATIONSV
R
2527
2-f2-[(5-Bromo-2-hydroxyphenyl)methylidene]hydrazinylg-1,3-thiazol-4(5H)-one (3)
White powder (dioxane); Yield 85%; m.p: 291–92 C; IR (KBr) cm1: 3429 broad (OH,
NH), 3028, 2962 (CH), 1716 (C¼O), 1643 (C¼N), 1593 (C¼C). Anal. calcd. for
C10H8BrN3O2S (314.16): C, 38.23; H, 2.57; Br, 25.43; N, 13.38; S, 10.21. Found: C, 38.
30; H, 2.48; Br, 25.49; N, 13.43; S, 10.30%.
6-Bromo-3-(2-(2-(5-bromo-2-hydroxybenzylidene)hydrazinyl)-thiazole-4-yl)-2H-
chromen-2-one (4)
Pale yellow powder (dioxane); Yield 89%; m.p: 275–76 C; 1H NMR: (400 MHz, DMSO-
d6, d, ppm): 6.84 (d,1H, J ¼ 8 Hz), 7.33–7.45 (m, 2H), 7.72–7.78 (m, 2H), 8.08 (s, 1H),
8.25 (s, 1H), 8.46 (s, 1H), 8.52 (s, 1H, CH¼N), 10.49 (s, 1H, NH), 12.25 (s, 1H, OH).
Anal. calcd. for C19H11Br2N3O3S(521.18): C, 43.79; H, 2.13; Br, 30.66; N, 8.06; S, 6.15.
Found: C, 43.72; H, 2.19; Br, 30.60; N, 8.12; S, 6.21%.
Biological screening
Antibacterial activity of the newly synthesized compounds was determined in vitro by
standardized disk – agar diffusion method.[51] Cultures of four bacterial species, namely,
Gram-positive bacteria: Enterococcus faecalis (ATCC 29212) and Staphylococcus aureus
(ATCC 25923), Gram-negative bacteria: Escherichia coli (ATCC 25922) and pseudo-
monas aeruginosa (ATCC 27853), were used to investigate the antibacterial activity of
the newly synthesized compounds.
Conclusions
In the present study, 1-(5-bromo-2-hydroxybenzylidene)thiosemicarbazide (2) was used
as a starting material for the synthesis of thiazoles and arylazothiazoles via reaction with
a-haloketones, a-haloesters and/or hydrazonoyl halides. Also, pyrazole-thiazole-couma-
rin (PTC) hybrid was prepared via reaction of 6-bromo-3-(2-hydrazinylthiazol-4-yl)-2H-
chromen-2-one (8) with dicarbonyl compounds. Eleven of the newly synthesized
compounds were screened for their antibacterial activity. The results revealed that com-
pounds 5a, 5b, 9a, 9c, 11b, and 12 were strong active towards Gram-positive bacteria
Enterococcus faecalis. Compound 5a was strongly active towards Gram-positive bacteria
Staphylococcus aureus. Whereas, compounds 9b, 11b, and 12 were strong active towards
Gram-negative bacteria Pseudomonas aeruginosa.
2528 A. ABDEL-AZIEM ET AL.
Disclosure statement
No potential conflict of interest was reported by the author(s).
ORCID
Anhar Abdel-Aziem http://orcid.org/0000-0002-3871-3183
References
[1] _
Eryılmaz, S.; Çelikoglu, E. T.; Idil, _
O.; Inkaya, E.; Kozak, Z.; Mısır, E.; G€
ul, M. Bioorg.
Chem. 2020, 95, 103476. DOI: 10.1016/j.bioorg.2019.103476.
[2] Reddy, G. M.; Garcia, J. R.; Reddy, V. H.; de Andrade, A. M.; Camilo, A.; Pontes Ribeiro,
R. A.; de Lazaro, S. R. Eur. J. Med. Chem. 2016, 123, 508–513. DOI: 10.1016/j.ejmech.
2016.07.062.
[3] Bondock, S.; Fadaly, W.; Metwally, M. A. Eur. J. Med. Chem. 2010, 45, 3692–3701. DOI:
10.1016/j.ejmech.2010.05.018.
[4] Kashyap, S. J.; Garg, V. K.; Sharma, P. K.; Kumar, N.; Dudhe, R.; Gupta, J. K. Med. Chem.
Res. 2012, 21, 2123–2132. DOI: 10.1007/s00044-011-9685-2.
[5] Meghdadi, M.; Amirnasr, E.; Yavari, K.; Mereiter, M.; Bagheri, C. R. Chim. 2017, 20,
730–737. DOI: 10.1016/j.crci.2017.02.005.
[6] Biernasiuk, A.; Kawczy nska, M.; Berecka-Rycerz, A.; Rosada, B.; Gumieniczek, A.; Malm,
A.; Dzitko, K.; Ła˛czkowski, K. Z. Med. Chem. Res. 2019, 28, 2023–2036. DOI: 10.1007/
s00044-019-02433-2.
[7] Ansari, A.; Ali, A.; Asif, M.; Rauf, M. A.; Shamsuzzaman, O. M. Steroids. 2018, 134, 22.
DOI: 10.1016/j.steroids.2018.04.003.
[8] Ouf, S. A.; Gomha, S. M.; Ewies, M. M.; Sharawy, I. A. A. J. Heterocyclic Chem. 2018, 55,
258–264. DOI: 10.1002/jhet.3040.
[9] Sondhi, S. M.; Singh, N.; Lahoti, A. M.; Bajaj, K.; Kumar, A.; Lozach, O.; Meijer, L.
Bioorg. Med. Chem. 2005, 13, 4291–4299. DOI: 10.1016/j.bmc.2005.04.017.
[10] Siddiqui, N.; Arya, S. K.; Ahsan, W.; Azad, B. Int. J. Drug Dev. Res. 2011, 3, 55.
[11] Mohareb, R. M.; Zaki, M. Y.; Abbas, N. S. Steroids. 2015, 98, 80–91. DOI: 10.1016/j.ste-
roids.2015.03.001.
[12] Satoh, A.; Nagatomi, Y.; Hirata, Y.; Ito, S.; Suzuki, G.; Kimura, T.; Maehara, S.; Hikichi,
H.; Satow, A.; Hata, M.; et al. Bioorg. Med. Chem. Lett. 2009, 19, 5464–5468. DOI: 10.
1016/j.bmcl.2009.07.097.
[13] Siddiqui, N.; Ahsan, W. Eur. J. Med. Chem. 2010, 45, 1536–1543. DOI: 10.1016/j.ejmech.
2009.12.062.
[14] Vu, C. B.; Bemis, J. E.; Disch, J. S.; Ng, P. Y.; Nunes, J. J.; Milne, J. C.; Carney, D. P.;
Lynch, A. V.; Smith, J. J.; Lavu, S.; et al. J. Med. Chem. 2009, 52, 1275–1283. DOI: 10.
1021/jm8012954.
[15] Iqbal, A. M.; Khan, A. Y.; Kalashetti, M. B.; Belavagi, N. S.; Gong, Y. D.; Khazi, I. A. M.
Eur. J. Med. Chem. 2012, 53, 308–315. DOI: 10.1016/j.ejmech.2012.04.015.
[16] Paudel, Y. N.; Ali, M. R.; Shah, S.; Adil, M.; Akhtar, M. S.; Wadhwa, R.; Bawa, S.; Sharma,
M. Biomed. Pharmacother. 2017, 89, 651–659. DOI: 10.1016/j.biopha.2017.02.043.
[17] Zia, M.; Akhtar, T.; Hameed, S.; Al-Masoudi, N. A. Z. Naturforsch. B Chem. Sci. 2012, 67,
747–758. DOI: 10.5560/znb.2012-0095.
[18] Rouf, A.; Tanyeli, C. Eur. J. Med. Chem. 2015, 97, 911–927. DOI: 10.1016/j.ejmech.2014.
10.058.
[19] Prashantha, T.; Avinb, B. R. V.; Thirusangub, P.; Ranganathac, V. L.; Prabhakarb, B. T.;
Chandrad, J. N. N. S.; Khanuma, S. A. Biomed. Pharmacother. 2019, 112, 108707. DOI:
10.1016/j.biopha.2019.108707.
SYNTHETIC COMMUNICATIONSV
R
2529
[20] Ła˛czkowski, K. Z.; Anusiak, J.; Switalska, M.; Dzitko, K.; Cytarska, J.; Baranowska-
Ła˛czkowska, A.; Plech, T.; Paneth, A.; Wietrzyk, J.; Białczyk, J. Med. Chem. Res. 2018, 27,
1131–1148. DOI: 10.1007/s00044-018-2136-6.
[21] Anuradha, S.; Patel, R.; Patel, P.; Parameswaran, A.; Jain, AS., Eur. J. Pharm. Sci. 2019,
134, 20. DOI: 10.1016/j.ejps.2019.04.005.
[22] Karaman, B.; G€ uzeldemirci, N. U. Med. Chem. Res. 2016, 25, 2471–2484. DOI: 10.1007/
s00044-016-1684-x.
[23] Abdelhamid, A. O.; Gomha, S. M.; Abdelriheem, N. A.; Kandeel, S. M. Molecules. 2016,
21, 929. DOI: 10.3390/molecules21070929.
[24] Gomha, S. M.; Abdelhamid, A. O.; Kandil, O. M.; Kandeel, S. M.; Abdelrehem, N. A.
Mini Rev Med Chem. 2018, 18, 1670–1682. DOI: 10.2174/1389557518666180424113819.
[25] Sayed, A. R.; Gomha, S. M.; Taher, E. A.; Muhammad, Z. A.; El-Seedi, H. R.; Gaber,
H. M.; Ahmed, M. M. Drug Des. Devel. Ther. 2020, 14, 1363–1375. DOI: 10.2147/DDDT.
S221263.
[26] Gomha, S. M.; Edrees, M. M.; Altalbawy, F. M. A. IJMS. 2016, 17, 1499. DOI: 10.3390/
ijms17091499.
[27] Asif, M.; Ali, A.; Zafar, A.; Farhan, M.; Khanam, H.; Hadi, S. M. Shamsuzzaman, J.
Biology. 2017, 166, 104. DOI: 10.1016/j.jphotobiol.2016.11.010.
[28] Abumelha, H. M. A. J. Heterocyclic Chem. 2020, 57, 1011–1022. DOI: 10.1002/jhet.3820.
[29] Crews, P.; Kakou, Y.; Quinoa, E. J. Am. Chem. Soc. 1988, 110, 4365–4368. DOI: 10.1021/
ja00221a042.
[30] Borges, F.; Roleira, F.; Milhazes, N.; Santana, L.; Uriarte, E. Curr. Med. Chem. 2005, 12,
887–916. DOI: 10.2174/0929867053507315.
[31] Vazquez-Rodriguez, S.; Matos, M. J.; Borges, F.; Uriarte Santana, E. L. Curr. Top. Med.
Chem. 2015, 15, 1755–1766. DOI: 10.2174/1568026615666150427125916.
[32] Widelski, J.; Luca, S. V.; Skiba, A.; Chinou, I.; Marcourt, L.; Wolfender, J.; Skalicka-
Wozniak, K. Molecules. 2018, 23, 1222. DOI: 10.3390/molecules23051222.
[33] Thomas, V.; Giles, D.; Basavarajaswamy, P. M. G.; Das, A. K.; Patel, A. Anticancer Agent.
Med. Chem. 2017, 17, 415–423. DOI: 10.2174/1871520616666160902094739.
[34] Desai, N. C.; Karkar, T. J.; Vekariya, R. H.; Joshi, S. B.; Jadeja, K. A.; Vaja, D. V. Indian J.
Chem. 2020, 59B, 231.
[35] Gomha, S. M.; Abdel-Aziz, H. M.; Badrey, M. G.; Abdulla, M. M. J. Heterocyclic Chem.
2019, 56, 1275–1282. DOI: 10.1002/jhet.3487.
[36] Perez-Cruz, K.; Moncada-Basualto, M.; Morales-Valenzuela, J.; Barriga-Gonzalez, G.;
Navarrete-Encina, P.; N un~ez-Vergara, L.; Squella, J. A.; Olea-Azar, C. Arab. J. Chem.
2018, 11, 525–537. DOI: 10.1016/j.arabjc.2017.05.007.
[37] Shen, Y.; Liu, L.; Feng, C.; Hu, Y.; Chen, C.; Wang, G.; Zhu, B. Fish Shellfish Immunol.
2018, 81, 57–66. DOI: 10.1016/j.fsi.2018.07.005.
[38] Hu, Y.; Xu, Z.; Zhang, S.; Wu, X.; Ding, J.; Lv, Z.; Feng, L. Eur. J. Med. Chem. 2017, 136,
122–130. DOI: 10.1016/j.ejmech.2017.05.004.
[39] Breckenridge, A. Semin. Hematol. 1978, 15, 19.
[40] Abdel-Aziem, A. J. Heterocycl. Chem. 2015, 52, 251. DOI: 10.1002/jhet.2390.
[41] Abdul Rahman, F. S.; Yusufzai, S. K.; Osman, H.; Mohamad, D. J. Phy. Sci. 2016, 27, 77.
[42] Pardo-Jimenez, V.; Navarrete-Encina, P.; Dıaz-Araya, G. Molecules. 2019, 24, 739. DOI:
10.3390/molecules24040739.
[43] _ G€
Koca, I.; um€ € ur, A.; Dişli, A.; Tutar, Y. Anticancer Agent. Med. Chem. 2015,
uş, M.; Ozg€
15, 916–930. DOI: 10.2174/1871520615666150407155623.
[44] Gabr, M. T.; El-Gohary, N. S.; El-Bendary, E. R.; El-Kerdawy, M. M.; Ni, N. Excli. J. 2017,
16, 1114–1131. DOI: 10.17179/excli2017-208.
[45] Kumar, S.; Saini, V.; Maurya, I. K.; Sindhu, J.; Kumari, M.; Kataria, R.; Kumar, V. PLOS
One. 2018, 13, e0196016. DOI: 10.1371/journal.pone.0196016.
[46] Joseph, J.; Mary, N. L.; Sidambaram, R. Synth. React. Inorg. Metal Org. Nano-Metal Chem.
2010, 40, 930–933. DOI: 10.1080/15533174.2010.522661.
2530 A. ABDEL-AZIEM ET AL.
[47] Zhuravel, I. O.; Kovalenko, M. S.; Vlasov, S. V.; Chernykh, P. V. Molecules. 2005, 10,
444–456. DOI: 10.3390/10020444.
[48] Eweiss, N. E.; Osma, A. Tetrahedron Lett. 1979, 20, 1169–1170. DOI: 10.1016/S0040-
4039(01)86092-5.
[49] Shawali, A. S.; Osman, A. Tetrahedron. 1971, 27, 2517–2528. DOI: 10.1016/S0040-
4020(01)90753-7.
[50] Abdelhamid, A. O.; Attaby, F. A.; Zaki, M. Y. Sulfur, Silicon, Relat Elem. 1990, 53,
403–410. DOI: 10.1080/10426509008038050.
[51] Bauer, A. W.; Kirby, W. W. M.; Sherris, J. C.; Turck, M. Am. J. Clin. Pathol. 1966, 45,
493–496. DOI: 10.1093/ajcp/45.4_ts.493.